Investigating the anticancer potential of 4-phenylthiazole derived Ru(ii) and Os(ii) metalacycles
- Authors: Getreuer P.; Marretta L.; Toyoglu E.; Dömötör O.; Hejl M.; Prado-Roller A.; Cseh K.; Legin A.A.; Jakupec M.A.; Barone G.; Terenzi A.; Keppler B.K.; Kandioller W.
- Publication year: 2024
- Type: Articolo in rivista
- OA Link: http://hdl.handle.net/10447/639698
Abstract
In this contribution we report the synthesis, characterization and in vitro anticancer activity of novel cyclometalated 4-phenylthiazole-derived ruthenium(ii) (2a-e) and osmium(ii) (3a-e) complexes. Formation and sufficient purity of the complexes were unambigiously confirmed by H-1-, C-13- and 2D-NMR techniques, X-ray diffractometry, HRMS and elemental analysis. The binding preferences of these cyclometalates to selected amino acids and to DNA models including G-quadruplex structures were analyzed. Additionally, their stability and behaviour in aqueous solutions was determined by UV-Vis spectroscopy. Their cellular accumulation, their ability of inducing apoptosis, as well as their interference in the cell cycle were studied in SW480 colon cancer cells. The anticancer potencies were investigated in three human cancer cell lines and revealed IC50 values in the low micromolar range, in contrast to the biologically inactive ligands.